deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT02353819

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

Phase I Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets for Patients With High Risk Prostate Cancer

Sponsor: National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Updated 19 times since 2017 Last updated: Feb 19, 2026 Started: Oct 31, 2015 Primary completion: Jan 31, 2030 Completion: Dec 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Prostate Cancer, this trial is ongoing. The trial is conducted by National Institute for Biomedical Imaging and Bioengineering (NIBIB) and has accumulated 19 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Feb 2023 · 11 months · monthly snapshot~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Feb 2026 · 11 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded
  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

Show 14 earlier versions
  1. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  8. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  10. Apr 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  11. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  13. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)
  • University of Texas Southwestern Medical Center
Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations